Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 96

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 96
---
, the pre-Merger equity holders of Telomir are expected to hold approximately 50% of the outstanding shares of Telomir, on a non-diluted basis, and the pre-Merger equity holders of TELI are expected to hold approximately 50% of the outstanding shares of Telomir Common Stock, on non-fully diluted basis. When taking into account the issuance of the Warrants, 41% of the outstanding shares of TELI Common Stock and the pre-Merger equity holders of TELI are expected to hold approximately 59% of the outstanding shares of Telomir Common Stock, on a fully-diluted basis.

The terms of, reasons for and other aspects of the Merger Agreement, the Merger, the issuance of TELO Common Stock pursuant to the Merger Agreement and the change of control resulting from the Merger are described in detail in the other sections in this proxy statement.

Required Vote

The affirmative vote of a majority of the votes cast virtually or by proxy at the TELO Annual Meeting is required to approve Proposal No. 1. Abstentions and broker non-votes will have no effect on the outcome of this proposal. It is anticipated that Proposal No. 1 will be a nondiscretionary proposal considered non-routine under the rules of the Nasdaq, which generally controls the ability of brokers to vote or not vote shares held in street name on certain matters, and thus may result in broker non-votes.

THE TELO BOARD RECOMMENDS THAT TELO’S STOCKHOLDERS VOTE “FOR” PROPOSAL NO. 1 TO APPROVE (I) THE ISSUANCE OF SHARES OF TELO COMMON STOCK OR OTHER SECURITIES OF TELO PURSUANT TO THE MERGER, WHICH WILL REPRESENT MORE THAN 20% OF THE SHARES OF TELO COMMON STOCK OUTSTANDING IMMEDIATELY PRIOR TO THE MERGER. THE APPROVAL OF PROPOSAL NO. 1 IS REQUIRED TO CONSUMMATE THE MERGER.

<div align='center'>PROPOSAL 2. ELECTION OF DIRECTORS</div>

Our Board is currently composed of four (4) members. Directors hold office until the next annual meeting of stockholders of the Company or until their earlier death, resignation, or removal, or until their successors are elected and qualified.

Information Regarding our Directors

Our Corporate Governance and Nominating Committee (the “Nominating Committee”) recommended, and our Board approved Erez A